Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma - updated results after 18-year follow-up.

Autor: Abdallah N; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Witzig TE; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Kumar SK; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Roy V; Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA., Gertz MA; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA., Bergsagel PL; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA., Rajkumar SV; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA. rajkumar.vincent@mayo.edu.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2024 May; Vol. 38 (5), pp. 1169-1171. Date of Electronic Publication: 2024 Feb 28.
DOI: 10.1038/s41375-024-02192-z
Databáze: MEDLINE
Externí odkaz: